U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07517185) titled 'The HIt HArd and hiT Early in Multiple Sclerosis Trial' on Nov. 21, 2025.
Brief Summary: The HiHat trial is a Phase 2 study aimed at evaluating the safety and feasibility of sequential treatment with rituximab and cladribine in patients with relapsing-remitting multiple sclerosis (RRMS). The study follows a prospective, open-label, single-arm design, with 60 RRMS patients receiving both treatments in a controlled regimen: two cycles of rituximab (1,000 mg each, biweekly) followed by two cycles of cladribine (30 mg per cycle for three days per cycle) spaced one month apart. Participants are monitored over 24 months through clinical a...